Panzyga clinical trials
How each study uses Panzyga is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Panzyga studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Panzyga
- 4
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Panzyga.
- Aug 2027IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 AntibodiesPhase 2 · Endeavor Health
Studies
Open first, then newest update. How each study uses Panzyga is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent InfectionsRecruitingPhase 3OctapharmaNCT07220915Written as Panzyga, 10% Intravenous Solution
- Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) PatientsRecruitingPhase 3OctapharmaNCT04929236Written as Panzyga
- IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 AntibodiesRecruitingPhase 2Endeavor HealthNCT04153422Written as Panzyga IVIG
- Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)CompletedPhase 3OctapharmaNCT04502030Written as Panzyga
- Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)CompletedPhase 3OctapharmaNCT04508530Written as Panzyga
- Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)TerminatedPhase 4OctapharmaNCT03866798Written as Panzyga
What changed recently
From the registry's own updates since Oct 18, 2026.
Codes
What other systems call Panzyga · ClinicalTrials.gg INT000658
- MeSH (NLM) C000617884PanzygaOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000617884 | Panzyga | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.